Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEPANIL vs TENUATE DOSPAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TEPANIL (diethylpropion) is a sympathomimetic amine that acts as a norepinephrine reuptake inhibitor in the hypothalamus, increasing norepinephrine levels in the synaptic cleft, which stimulates beta-2 adrenergic receptors, leading to appetite suppression.
Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.
FDA-approved: Short-term (8-12 weeks) adjunctive therapy for weight management in patients with a body mass index (BMI) ≥30 kg/m² or BMI ≥27 kg/m² in the presence of obesity-related risk factors (e.g., hypertension, diabetes, dyslipidemia). Off-label: None commonly recognized.
Short-term adjunct in exogenous obesity,FDA-approved for obesity management
25 mg orally three times daily, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
4-6 hours; clinical context: requires multiple daily dosing for sustained anorectic effect
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function, though clinical effects may last longer due to tissue distribution.
Hepatic metabolism via CYP450 isoenzymes, primarily N-dealkylation and deamination. Active metabolites include N-ethyl- and N,N-diethyl- derivatives.
Hepatic via CYP3A4 and other CYP enzymes
Renal: 90% (as metabolites and unchanged drug), Fecal: <10%
Renal excretion of unchanged drug and metabolites; approximately 85-90% of the dose is excreted in urine within 48 hours, with less than 5% in feces.
30-40% bound to albumin
Approximately 20-30% bound to plasma proteins.
3-4 L/kg; indicates extensive tissue distribution
Approximately 5-10 L/kg, indicating extensive tissue distribution.
Oral: 60-70% due to first-pass metabolism
Rapidly absorbed from the gastrointestinal tract; absolute oral bioavailability is about 10-20% due to extensive first-pass hepatic metabolism.
Contraindicated in end-stage renal disease. For GFR <30 m L/min: not recommended. For GFR 30-59 m L/min: use with caution and monitor for adverse effects.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), use with caution and consider dose reduction.
Contraindicated in severe hepatic impairment. For Child-Pugh Class B: reduce dose by 50% or consider alternative. For Child-Pugh Class A: no adjustment required.
Contraindicated in severe hepatic impairment. For Child-Pugh A or B, use with caution and consider reducing dose to 12.5 mg twice daily.
Not recommended for use in children below 16 years of age due to lack of safety and efficacy data.
Not recommended for use in children under 12 years. For adolescents 12-17 years, same adult dosing may be used under strict supervision.
Starting dose of 25 mg once daily in the morning, with slow titration upwards. Monitor for cardiovascular and psychiatric effects due to increased sensitivity.
Initiate at lower dose (12.5 mg twice daily) due to increased sensitivity and risk of adverse effects. Maximum dose 75 mg per day.
None.
None
Pulmonary hypertension: Cases of primary pulmonary hypertension (PPH) have been reported; avoid in patients with known pulmonary hypertension.,Valvular heart disease: Association with regurgitant cardiac valvular disease; avoid in patients with structural cardiac abnormalities.,Serotonin syndrome: Risk when co-administered with serotonergic drugs or MAOIs; allow 14 days after MAOI discontinuation.,CNS stimulation: May cause dizziness, insomnia, and euphoria; avoid with alcohol or other CNS stimulants.,Tolerance/dependence: Tolerance develops with prolonged use; potential for psychological dependence; limit use to 8-12 weeks.,Hypertension: Monitor blood pressure; exacerbate pre-existing hypertension.
Pulmonary hypertension,Valvular heart disease,Seizures,Psychiatric disturbances,Tolerance and dependence,May impair ability to drive or operate machinery
History of pulmonary hypertension or valvular heart disease.,Hyperthyroidism.,Glaucoma.,Agitated states.,History of drug abuse.,Concurrent use or within 14 days of MAOIs.,Hypersensitivity to diethylpropion or sympathomimetic amines.,Pregnancy and lactation.
Advanced arteriosclerosis,Cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,During or within 14 days of MAOI therapy
Avoid caffeine, as it may increase stimulant effects and risk of palpitations. Avoid alcohol, which can potentiate CNS effects and increase seizure risk. Take with food if gastrointestinal upset occurs.
No specific food interactions. However, avoid excessive caffeine intake as it may increase stimulant effects. Take with or without food; high-fat meals may delay absorption.
Pregnancy Category X. TEPANIL (diethylpropion) is contraindicated in pregnant women due to anorectic effects potentially causing fetal malnutrition and growth restriction. First trimester exposure may increase risk of neural tube defects, though human data limited. Second and third trimester exposure may lead to reduced birth weight and neonatal withdrawal symptoms including irritability and tremors.
FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the first trimester. Potential for neonatal withdrawal symptoms (hyperexcitability, feeding disorders) with third trimester exposure.
Excreted into breast milk; milk-to-plasma ratio not established. Potential for adverse effects in nursing infants including irritability and feeding difficulties. Contraindicated in breastfeeding due to risk of infant exposure and lack of safety data.
Excretion in human milk unknown; risk of serious adverse reactions in nursing infants (e.g., CNS stimulation, growth suppression). Use during breastfeeding contraindicated. M/P ratio not established.
No dose adjustment is recommended or studied in pregnancy as drug is contraindicated. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism) would likely reduce drug exposure; however, given fetal risks, use is not justified. Avoid use entirely.
No dose adjustment possible; drug contraindicated entirely during pregnancy due to known teratogenicity. If pregnancy occurs, discontinue immediately and manage with alternative therapy.
TEPANIL is a schedule IV controlled substance; assess for history of substance abuse before prescribing. Avoid use in patients with cardiovascular disease, hyperthyroidism, glaucoma, or agitated states. Monitor blood pressure and heart rate regularly. Use only for short-term (8-12 weeks) as tolerance develops. Do not combine with MAOIs or within 14 days of MAOI use. May cause insomnia; advise last dose before 6 PM.
TENUATE DOSPAN (diethylpropion) is a schedule IV controlled substance used as an adjunct in obesity management. Avoid concurrent use with MAOIs due to hypertensive crisis risk. Monitor for tachyphylaxis and potential for abuse; limit use to short-term (up to 12 weeks). Contraindicated in patients with hyperthyroidism, glaucoma, or history of drug abuse.
Take exactly as prescribed; do not increase dose or frequency due to abuse potential.,May cause dizziness or blurred vision; avoid driving until you know how this medicine affects you.,Report chest pain, shortness of breath, or leg swelling immediately.,Avoid alcohol and caffeine-containing products while taking this medication.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Tell your doctor if you have a history of drug abuse or mental health issues.
Take exactly as prescribed; do not increase dose or frequency.,Do not crush or chew the controlled-release tablet; swallow whole.,Report any chest pain, palpitations, or shortness of breath immediately.,Avoid alcohol and other CNS stimulants.,Use caution when driving or operating machinery until you know how this drug affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEPANIL vs TENUATE DOSPAN, answered by our medical review team.
TEPANIL is a Sympathomimetic anorectic that works by TEPANIL (diethylpropion) is a sympathomimetic amine that acts as a norepinephrine reuptake inhibitor in the hypothalamus, increasing norepinephrine levels in the synaptic cleft, which stimulates beta-2 adrenergic receptors, leading to appetite suppression.. TENUATE DOSPAN is a Sympathomimetic anorectic that works by Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEPANIL and TENUATE DOSPAN depend on the specific clinical indication. These are both Sympathomimetic anorectic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEPANIL is: 25 mg orally three times daily, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.. The standard adult dose of TENUATE DOSPAN is: 25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEPANIL and TENUATE DOSPAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEPANIL is classified as Category C. Pregnancy Category X. TEPANIL (diethylpropion) is contraindicated in pregnant women due to anorectic effects potentially causing fetal malnutrition and growth restriction. First tr. TENUATE DOSPAN is classified as Category C. FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the fi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.